Loading…
Syndax Pharmaceuticals, Inc. is projected to rise to $26.33 by 2027, a +34% move from its current price of $19.61. SNDX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $19.12 | $19.61 | $20.11 | 0.00% |
| May 30 | $18.92 | $19.61 | $20.32 | -0.01% |
| May 31 | $18.77 | $19.61 | $20.49 | -0.01% |
| Jun 1 | $18.64 | $19.61 | $20.63 | -0.01% |
| Jun 2 | $18.53 | $19.61 | $20.75 | -0.02% |
| Jun 3 | $18.43 | $19.61 | $20.86 | -0.02% |
| Jun 4 | $18.33 | $19.60 | $20.96 | -0.03% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $18.33 | $19.60 | $20.96 | -0.03% |
| Week 2 | $17.83 | $19.60 | $21.55 | -0.05% |
| Week 3 | $17.45 | $19.59 | $22.01 | -0.08% |
| Week 4 | $17.13 | $19.59 | $22.40 | -0.10% |
| Week 5 | $16.86 | $19.58 | $22.75 | -0.13% |
| Week 6 | $16.61 | $19.58 | $23.07 | -0.16% |
| Week 7 | $16.39 | $19.57 | $23.37 | -0.18% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing therapies for cancer.
Its lead products include Revuforj (revumenib), a menin inhibitor for relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
The company also pursues revumenib for R/R AML with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. Syndax was incorporated in 2005 and is headquartered in New York, New York.
Syndax Pharmaceuticals, Inc. (SNDX) is a Healthcare stock with a current price of $19.94 and a market cap of $1.77B. It ranks 2091 in market capitalization. The overall price outlook, based on the supplied multi-year forecast, shows bullish momentum ahead, with upside potential over the coming years.
A major floor 19.4% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.5% away) — a key level to hold.
The nearest ceiling, 24.1% above — a clean break opens room to run.
A major ceiling 33.8% above — clearing it would confirm fresh momentum.
Key SNDX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SNDX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $19.87 | Sell | $19.81 | Sell |
| MA 10 | $19.98 | Sell | $20.00 | Sell |
| MA 20 | $20.27 | Sell | $20.48 | Sell |
| MA 50 | $22.28 | Sell | $21.35 | Sell |
| MA 100 | $21.77 | Sell | $21.07 | Sell |
| MA 200 | $19.25 | Buy | $19.55 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.16 | Neutral |
| Stoch RSI (14) | 32.84 | Neutral |
| CCI (20) | -80.55 | Neutral |
| Williams %R (14) | -88.26 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | -8.75 | Sell |
| Bollinger %B (20,2) | 0.25 | Neutral |
| Stochastic %K (14) | 11.74 | Buy |
| TRIX (15) | -0.50 | Sell |
| Awesome (5,34) | -1.58 | Sell |
| Ultimate (7,14,28) | 38.40 | Neutral |
| Momentum (10) | -0.80 | Sell |
| Aroon Osc (25) | -32.00 | Sell |
| Hull MA (9) | 19.82 | Sell |
| ADX (14) | 18.57 | Neutral |
| ATR (14) | 0.46 | Info |
The 30-day technical picture is bullish, with RSI(14) at 40, SMA(50) at $22.44, and SMA(200) at $19.18. The stock sits near support at $19.11 and faces resistance at $24.43. The 30-day trading range spans $16.71 to $23.79, and annualized volatility stands around 50%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $19.11 | $19.61 | $26.45 | 0% | Neutral | |
| $21.03 | $26.33 | $34.84 | +34% | Bullish | |
| $22.85 | $29.34 | $40.14 | +50% | Bullish | |
| $25.80 | $33.82 | $47.51 | +72% | Bullish | |
| $26.96 | $36.01 | $51.74 | +84% | Bullish | |
| $25.62 | $34.80 | $51.00 | +77% | Bullish | |
| $29.14 | $40.19 | $59.96 | +105% | Bullish | |
| $32.99 | $46.19 | $70.02 | +136% | Bullish | |
| $37.03 | $52.58 | $80.90 | +168% | Bullish | |
| $41.69 | $59.99 | $93.58 | +206% | Bullish | |
| $54.04 | $82.61 | $136.60 | +321% | Bullish | |
| $91.83 | $155.70 | $280.35 | +694% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $19.11 | $19.61 | $23.08 | +0.00% |
| June 2026 | $16.87 | $19.79 | $23.73 | +0.89% |
| July 2026 | $16.54 | $19.54 | $23.73 | -1.22% |
| August 2026 | $16.93 | $20.13 | $24.68 | +3.01% |
| September 2026 | $17.43 | $20.83 | $25.74 | +3.48% |
| October 2026 | $17.18 | $20.62 | $25.67 | -1.01% |
| November 2026 | $16.97 | $20.45 | $25.61 | -0.83% |
| December 2026 | $17.35 | $21.00 | $26.45 | +2.68% |
Click any year to see its month-by-month SNDX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The SNDX price prediction for 2026 points to an average of $19.61 (low $19.11, high $26.45) — a potential gain of 0% on today's $19.61. Price action looks broadly range-bound.
In 2027, SNDX is projected to trade between $21.03 and $34.84, averaging $26.33 — a potential gain of +34% from today's $19.61. That is up +34% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Syndax Pharmaceuticals, Inc.'s 2028 outlook centres on $29.34, within a $22.85 to $40.14 range. That is up +11% on the projected 2027 average. That marks a +50% change versus current levels. Momentum favours further upside here.
By 2029, SNDX could reach as high as $47.51, with a base case around $33.82 and support toward $25.80 — roughly +72% from $19.61. Buyers look set to stay in control over this stretch.
Expect SNDX to range from $26.96 to $51.74 through 2030. The $36.01 average target implies a +84% move from current prices. That is up +6% on the projected 2029 average. Momentum favours further upside here.
The SNDX price prediction for 2031 points to an average of $34.80 (low $25.62, high $51.00) — a potential gain of +77% on today's $19.61. Buyers look set to stay in control over this stretch.
In 2032, SNDX is projected to trade between $29.14 and $59.96, averaging $40.19 — a potential gain of +105% from today's $19.61. That is up +16% on the projected 2031 average. Momentum favours further upside here.
Syndax Pharmaceuticals, Inc.'s 2033 outlook centres on $46.19, within a $32.99 to $70.02 range. That is up +15% on the projected 2032 average. That marks a +136% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, SNDX could reach as high as $80.90, with a base case around $52.58 and support toward $37.03 — roughly +168% from $19.61. Momentum favours further upside here.
Expect SNDX to range from $41.69 to $93.58 through 2035. The $59.99 average target implies a +206% move from current prices. That is up +14% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The SNDX price prediction for 2040 points to an average of $82.61 (low $54.04, high $136.60) — a potential gain of +321% on today's $19.61. Momentum favours further upside here.
In 2050, SNDX is projected to trade between $91.83 and $280.35, averaging $155.70 — a potential gain of +694% from today's $19.61. That is up +88% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in SNDX today (≈ 50.994391 SNDX) could be worth
$7,939.98
+$6,939.98 (+694%) by 2050 · US Dollar
Based on the average projected SNDX price of $155.7 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SNDXwould be worth at today's price.
$1,000 invested in SNDX on May 27, 2025 (≈ 100.704931 SNDX) would be worth
$1,974.82
+$974.82 (+97.5%) today · 1.97× · US Dollar
Based on a SNDX entry price of $9.93 vs. today's $19.61.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $20.13 | $974.17 | -2.6% |
| 1 month ago | $21 | $933.81 | -6.6% |
| 3 months ago | $20.67 | $948.72 | -5.1% |
| 6 months ago | $19.82 | $989.4 | -1.1% |
| 1 year ago | $9.93 | $1,974.82 | +97.5% |
| All time (5.0y) ago | $18.38 | $1,066.92 | +6.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SNDX forecast.
Our base-case forecast reaches $39.00 around 2032.
Implied market cap at $39.00: $3.46B
The multi-year forecast shows meaningful upside. In 2026 the average price is $19.94 with a min of $19.11 and a max of $27.29 (ROI 0, sentiment Neutral). In 2027 the average rises to $27.19 (ROI 36.3, bullish); 2028 to $30.58 (ROI 53.4); 2029 to $35.38 (ROI 77.4); 2030 to $37.41 (ROI 87.6); 2031 to $36.23 (ROI 81.7); 2032 to $42.36 (ROI 112.4); 2033 to $48.78 (ROI 144.7); 2034 to $55.81 (ROI 179.9); 2035 to $64.01 (ROI 221); 2040 to $89.07 (ROI 346.7); 2050 to $167.35 (ROI 739.3).
The sentiment is bullish across these years. These are estimates, not guarantees.
Tap a question to reveal the answer.
Avg $37.41; Min $27.75; Max $54.36; ROI 87.6; sentiment bullish.
Forecasts show bullish sentiment from 2027 onward with rising averages and ROIs (e.g., 2027 Avg $27.19; 2028 Avg $30.58; 2030 Avg $37.41; 2040 Avg $89.07; 2050 Avg $167.35; ROI up to 739.3). These are estimates, not guarantees.
Yes. The forecast max price reaches $101.32 in 2035, $149.77 in 2040, and $307.39 in 2050.
Current price $19.94; Market cap $1.77B.
Sentiment bullish; RSI(14) 40; SMA(50) $22.44; SMA(200) $19.18; Support $19.11; Resistance $24.43; 30-day range $16.71-$23.79; Annualized volatility 50%.
Syndax Pharmaceuticals, Inc. Community Discussion
0Share your Syndax Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.